GlassScriptPhysician profile
Mariko Pusinelli
NPI 1871203968
$4,679.80
in general payments reported to CMS, 2019-2025
51 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $115 · 2023: $1,866 · 2024: $1,553 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,223 · Education: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,223.30 |
| Education | $341.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $484.71 | 2022-2025 | Lynparza, Enhertu, Calquence |
| Novartis Pharmaceuticals Corporation | $371.64 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $228.84 | 2023-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Lilly USA, LLC | $219.58 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Janssen Biotech, INC. | $210.87 | 2023-2025 | Tecvayli, Rybrevant, Talvey |
| Gilead Sciences, INC. | $210.48 | 2023-2025 | Trodelvy |
| Genentech USA, INC. | $205.77 | 2024-2025 | Tecentriq, Itovebi, Tecentriq Hybreza |
| Pfizer INC. | $204.21 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $190.84 | 2023 | Imbruvica, Epkinly |
| Astellas Pharma US INC | $181.35 | 2023-2024 | Padcev |
| Daiichi Sankyo INC. | $177.71 | 2023-2025 | Injectafer, Enhertu, Datroway |
| Octapharma USA, INC. | $177.18 | 2023 | Octagam Immune Globulin (Human) |
| Eisai INC. | $156.99 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.76 | 2022-2024 | Alunbrig, Ninlaro |
| Abbvie INC. | $115.24 | 2024-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariko Pusinelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.